The Market Reports

Synopsis

The global market for Next-Generation Sequencing (NGS) Services was estimated to be worth US$ 21241 million in 2024 and is forecast to a readjusted size of US$ 65046 million by 2031 with a CAGR of 16.4% during the forecast period 2025-2031.

Next-Generation Sequencing (NGS) Services refer to comprehensive genetic analysis solutions based on high-throughput sequencing platforms, enabling the detection and analysis of genomic, transcriptomic, and epigenomic information at multiple levels. By leveraging parallelized, large-scale, and high-precision sequencing, NGS dramatically improves the efficiency and accuracy of genetic data acquisition, generating massive DNA or RNA sequence datasets in a single run. These services encompass the entire workflow, including sample preparation, library construction, sequencing operations, data processing, and bioinformatics analysis, while offering customized solutions for diverse needs such as research, clinical diagnostics, drug development, agricultural breeding, and microbiology studies. With advantages in cost efficiency, data depth, and application breadth, NGS services have become an essential infrastructure and innovation driver in precision medicine, life sciences, and the biotechnology industry.

The accelerated implementation of global precision medicine strategies and continuous advancements in bioinformatics are creating vast growth opportunities for the NGS services market. Increased government funding for genomics research and clinical translation projects such as early cancer screening is driving demand expansion among hospitals, research institutions, and biopharmaceutical companies. With significant reductions in sequencing costs and faster turnaround times, NGS has transitioned from exploratory research to large-scale clinical applications, covering areas such as tumor profiling, companion diagnostics, pathogen detection, and rare disease screening.

Across the value chain, deeper collaborations between platform technology providers, service operators, and downstream application sectors are accelerating the adoption of new service models and value-added applications.

Despite rapid growth, the NGS services market faces challenges such as the lack of standardized data interpretation protocols, stringent regulatory requirements for clinical applications, and compliance risks related to data security.

Regulatory differences across countries and regions increase the complexity of cross-border operations. High-quality bioinformatics analysis depends on experienced technical teams and robust computing infrastructure, creating barriers to entry. Certain niche segments demand extremely high sequencing accuracy and sensitivity, requiring continuous investment in R&D and quality control. Additionally, as market competition intensifies, balancing price pressures with differentiated service capabilities has become a critical test for business sustainability and expansion. In the coming years, downstream demand for NGS services will diversify and integrate across multiple sectors. In healthcare, personalized treatment and early disease screening will continue to expand, particularly in the precision diagnosis of cancer, infectious diseases, and genetic disorders. In the biopharmaceutical industry, NGS will play a key role in new drug target discovery, elucidating drug response mechanisms, and stratifying patients in clinical trials.

Agriculture and environmental sciences will further leverage NGS for crop improvement, animal breeding, and microbiome monitoring. Meanwhile, AI-driven automated analysis and cloud-based data collaboration will drive NGS services toward higher efficiency and broader accessibility, meeting the growing need for real-time, large-scale, multidimensional genetic information in both research and industrial applications.

This report aims to provide a comprehensive presentation of the global market for Next-Generation Sequencing (NGS) Services, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Next-Generation Sequencing (NGS) Services by region & country, by Type, and by Application.

The Next-Generation Sequencing (NGS) Services market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Sequencing (NGS) Services.

Market Segmentation

By Company

• Eurofins Scientific
• Natera
• BGI
• Illumina
• Roche
• LabCorp
• Berry Genomics
• Thermo Fisher Scientific
• Macrogen
• Oxford Nanopore
• Novogene
• Pacific Biosciences
• Azenta Life Sciences

Segment by Type

• Targeted Sequencing
• Whole Exome Sequencing
• Whole Genome Sequencing

Segment by Application

• Hospitals and Clinics
• Biopharma Companies
• Academic & Research Organizations
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.